Results 101 to 110 of about 31,180 (210)

The safe and effective use of tofacitinib and ustekinumab combination therapy in infantile onset inflammatory bowel disease

JPGN Reports, EarlyView.
Abstract Infantile‐onset inflammatory bowel disease (IOIBD) is a rare and severe subset of very‐early‐onset IBD, often associated with immune dysregulation and poor response to conventional therapies. Data regarding the use of Janus kinase inhibitors (JAKI) in this population is limited.
Smridhi Mahajan, Christian Wysocki, Bhaskar Gurram   +2 more
wiley   +1 more source

Acneiform eruption associated with Janus kinase inhibitors in pediatric inflammatory bowel disease: Case series and clinical management guidance

JPGN Reports, EarlyView.
Abstract Janus kinase inhibitors (JAKi) are increasingly used for refractory inflammatory bowel disease (IBD) in pediatric patients but are associated with significant dermatologic adverse effects. Acneiform eruptions have been reported in up to 30% of adults, with a greater incidence suspected in adolescents.
Tina H. Tran, Daniel Park, Regina‐Celeste Ahmad, Malika Goel, Sofia Verstraete, Sabina Ali   +5 more
wiley   +1 more source

Insight into Janus kinases specificity: From molecular architecture to cancer therapeutics

MedComm – Oncology
Janus Kinases (JAKs) play a crucial role as therapeutic targets for various cancers. However, the current JAK inhibitors (JAKi) available have limited therapeutic benefits due to their lack of selectivity.
Tian‐Hua Wei, Meng‐Yi Lu, Si‐Hui Yao, Yu‐Qi Hong, Jin Yang, Meng‐Yuan Zhang, Yu‐Qi Yin, Yu‐Jie Han, Qing‐Qing Li, Zi‐Xuan Wang, Yi‐Bo Wang, Zhen‐Jiang Tong, Yun Zhou, Wei‐Chen Dai, Yan‐Cheng Yu, Shan‐Liang Sun, Ye Yang, Nian‐Guang Li, Zhi‐Hao Shi   +18 more
doaj   +1 more source

Inhibitors Targeting Multiple Janus Kinases From Zanthoxylum simulans Mediate Inhibition and Apoptosis Against Gastric Cancer Cells via the Estrogen Pathway. [PDF]

Front Chem, 2022
Tian YQ, Hu D, Zhang YL, Zou J, Chen GL, Guo MQ.   +5 more
europepmc   +1 more source

Paradoxical Alopecia Areata Induced by IL‐17 and IL‐23 Inhibitors: A Systematic Review

JEADV Clinical Practice, EarlyView.
This systematic review identifies consistent clinical patterns of alopecia areata associated with IL‐17 and IL‐23 inhibitors, most frequently involving secukinumab and ustekinumab. Disease severity varied widely, and management often required biologic discontinuation or therapeutic switching.
Isabella Kamholtz, Simonetta I. Gaumond, Joaquin J. Jimenez   +2 more
wiley   +1 more source

Pseudorabies Virus Inhibits Type I and Type III Interferon-Induced Signaling via Proteasomal Degradation of Janus Kinases. [PDF]

J Virol, 2021
Yin Y, Romero N, Favoreel HW.
europepmc   +1 more source

Nail Lichen Planus in Children ‐ Epidemiology, Pathogenesis, Clinical Presentation, and Treatment

JEADV Clinical Practice, EarlyView.
ABSTRACT Nail lichen planus (NLP) is a chronic inflammatory disorder that, while rare in children compared to adults, represents a significant cause of pediatric nail dystrophy that requires early recognition to prevent permanent scarring and nail loss.
Francesca Pampaloni, Matilde Iorizzo
wiley   +1 more source

When Treatment Meets Natural History: Understanding Early Dermatitis‐Related Adverse Events in Systemic Atopic Dermatitis Trials

JEADV Clinical Practice, EarlyView.
ABSTRACT Biologics and Janus kinase (JAK) inhibitors have transformed the management of atopic dermatitis (AD), yet some patients experience early worsening of disease activity during treatment initiation. In clinical trials, these events are typically recorded as treatment‐emergent adverse events (TEAEs), most commonly coded as “atopic dermatitis”. We
Diego Ruiz Dasilva, Alondra Soto‐Gonzalez, Haya Alkiswani, Graham H. Litchman, Harrison Nguyen, Gil Yosipovitch, Firas George Hougeir, Matthew Zirwas, David Cotter, Brad Glick, E. James Song, Christopher G. Bunick, Neal Bhatia, Adam Friedman, Leon Kircik, Mona Shahriari, Peter Lio, James Del Rosso   +17 more
wiley   +1 more source

Real‐World Effectiveness and Safety of Topical Ruxolitinib in Adolescents With Vitiligo: A 52‐Week Retrospective Study

JEADV Clinical Practice, EarlyView.
Topical ruxolitinib 1.5% cream was assessed in 39 adolescents with non‐segmental vitiligo. Median T‐VASI fell at week 24 (n = 34) and week 52 (n = 18), with repigmentation most pronounced on the face: 55.6% reached F‐VASI50 at week 52. Few adverse events were recorded, all mild application‐site reactions in 4 of 39 patients.
L. Coronella, V. Picone, C. Costa, M. Napolitano   +3 more
wiley   +1 more source

Vaccarin Improves Myocardial Ischemia–Reperfusion Injury by Attenuating Oxidative Stress and Ferroptosis Through Reducing NOX4‐Modulated JAK2/STAT3 Pathway Activation

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Vaccarin is a naturally occurring flavonoid glycoside with cardioprotective properties; however, its involvement in myocardial ischemia–reperfusion (MI/R) injury remains poorly defined. We herein investigated whether vaccarin protects cardiomyocytes from MI/R‐induced dysfunction in vivo and in vitro and examined the associated molecular ...
Han Yang, Mi Zhou, Feng‐Cai Zhang
wiley   +1 more source